Jubilant Pharmova Limited has reported a robust 14% year-on-year revenue growth for the financial year ending March 31, 2026, reaching ₹8,280 crore. The company’s board has proposed a dividend of ₹5 per equity share, reflecting its strong financial performance.
The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased by 8% to ₹1,326 crore, although the EBITDA margin decreased by 99 basis points to 15.9%. The normalised profit after tax (PAT) rose by 7% to ₹442 crore, despite a decline in EBITDA margins due to temporary shutdowns and increased depreciation costs.
Jubilant Pharmova’s revenue growth was significantly driven by its Contract Development and Manufacturing Organisation (CDMO) Sterile Injectables business, which onboarded one of the world’s largest oncology products on its Line 3 in Spokane. This segment saw a 38% increase in revenue to ₹1,755 crore, although EBITDA margins were affected by the shutdown of the Montreal facility.
In the Radiopharmaceuticals segment, FY26 revenue grew by 10% to ₹1,178 crore. The company anticipates normalisation of revenue and EBITDA from H2’FY27 as production at CMO Montreal stabilises. The Allergy Immunotherapy business also experienced a 12% revenue growth to ₹785 crore, driven by increased demand in both US and international markets.
The company has also announced a strategic partnership with Pierre Fabre, France, to expand its footprint in Europe, particularly in biologics and Antibody-Drug Conjugates (ADCs). Furthermore, Jubilant Pharmova is investing in expanding its PET manufacturing network, with a proposed investment of US$ 50 million, aiming to become the second-largest radiopharmacy network in the US.
Jubilant Pharmova’s Drug Discovery business reported a 15% increase in revenue to ₹654 crore, while the API business faced challenges due to industry-wide pricing pressure, with revenue standing at ₹564 crore.
The company remains optimistic about its future growth prospects, with plans to stabilise production at its Montreal facility and commence commercial batch production of its new oncology product line in late FY27, subject to regulatory approvals.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).